A Study to Evaluate LTI-01 in Patients With Infected, Non-draining Pleural Effusions
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
The LTI-01-2001 study is a double-blind, placebo-controlled, Phase 2 study to evaluate LTI-01
(single-chain urokinase plasminogen activator, scuPA) in patients with infected, non-draining
pleural effusions.